Viewing data from:

LUBIPROSTONE

ANDA

LUBIPROSTONE | A218640 | ASCENT PHARMACEUTICALS INC

2 strengths0 unique patents0 unique exclusivities

Reference Listed Drug: AMITIZA(TE code: AB)

Drug Pricing (NADAC)

National Average Drug Acquisition Cost — Week of 2026-10-21 | 4 NDCs

Highest NADAC/Unit

$0.6456

per ea

Lowest NADAC/Unit

$0.5674

per ea

Brand NDCs

Generic NDCs

NDC Description	NADAC/Unit	Unit	Type	Generic NADAC	Effective
31722040460LUBIPROSTONE 24 MCG CAPSULE	$0.6456	EA	Generic	—	2026-10-21
72603028901LUBIPROSTONE 24 MCG CAPSULE	$0.6456	EA	Generic	—	2026-10-21
31722040360LUBIPROSTONE 8 MCG CAPSULE	$0.5674	EA	Generic	—	2026-10-21
72603028801LUBIPROSTONE 8 MCG CAPSULE	$0.5674	EA	Generic	—	2026-10-21

Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.

API Supply Chain8 active DMFs4 inactive

8 active API suppliers hold Drug Master Files for this ingredient.

SUCAMPO PHARMA AMERICAS LLCLUBIPROSTONE (RU-0211)

DMF 180912005

EVERLIGHT CHEMICAL INDUSTRIAL CORPLUBIPROSTONE

DMF 233832009

DR REDDYS LABORATORIES LTDLUBIPROSTONE

DMF 247052011

ZHEJIANG AUSUN PHARMACEUTICAL CO LTDLUBIPROSTONE

DMF 308022016

APOTEX PHARMACHEM INDIA PVT LTDLUBIPROSTONE

DMF 312752017

SUN PHARMACEUTICAL INDUSTRIES LTDLUBIPROSTONE

DMF 324722018

MSN LABORATORIES PRIVATE LTDLUBIPROSTONE

DMF 344162019

YS LIFE SCIENCE CO LTDLUBIPROSTONE

DMF 372812022

CATALENT PHARMA SOLUTIONS LLCInactiveLUBIPROSTONE, 24 MCG CAPSULES

DMF 180762005

TEVA PHARMACEUTICAL INDUSTRIES LTDInactiveLUBIPROSTONE

DMF 234022009

APOTEX PHARMACHEM INCInactiveLUBIPROSTONE

DMF 234902010

FIS FABBRICA ITALIANA SINTETICI SPAInactiveLUBIPROSTONE

DMF 242862010

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Products (2)

Sort:

#001 — 8MCG

0 patents0 exclusivities▴

CAPSULE;ORAL | Approved: Jan 2, 2025

No patent or exclusivity listings for this strength.

#002 — 24MCG

0 patents0 exclusivities▾

CAPSULE;ORAL | Approved: Jan 2, 2025